Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed <i>BCR</i>-<i>ABL</i>–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

Masamitsu Yanada, Jin Takeuchi, Isamu Sugiura et al. · Journal of Clinical Oncology · 2005 · 454 citations · Full text

Medicine, Hematology, Oncology +15

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Oliver G. Ottmann, Hervé Dombret, Giovanni Martinelli et al. · Blood · 2007 · 369 citations · Full text

Life Sciences, Hematology, Oncology +16

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study

Adrienne de Labarthe, Philippe Rousselot, Françoise Huguet‐Rigal et al. · Blood · 2006 · 344 citations · Full text

Medicine, Hematology, Oncology +14

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

Farhad Ravandi, Susan O’Brien, Deborah Thomas et al. · Blood · 2010 · 343 citations · Full text

Medicine, Hematology, Oncology +11